Inhibition of cGAS-STING signalling could be beneficial by preventing heart adverse remodelling in many disease settings, including cardiac hypertrophy [24], diabetic cardiomyopathy [25] and doxorubicin-induced cardiotoxicity [26]. The gene discussed is STING1; the disease is cardiac hypertrophy.